Genetic analysis and clinical significance of a rare t(1;12)(q21;p13) in a patient with high-risk myelodysplastic syndrome.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular genetics & genomic medicine"
DOI: 10.1002/mgg3.1893
Abstract: To explore the genetic and clinical features of a rare t(1;12)(q21;p13) in a patient with myelodysplastic syndrome (MDS). A 53-year-old male was diagnosed as high-risk MDS, and died in a short period. A complete cytogenetic… read more here.
Keywords: p13; q21 p13; p13 patient; rare q21 ... See more keywords
A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3291-z
Abstract: Dear Editor, The identification of recurrent gene rearrangements in the clinical laboratory is important for a precise diagnosis and treatment decisions in patients with acute leukemia [1]. Currently, cytogenetic tests and reverse transcription-PCR (RT-PCR) are… read more here.
Keywords: pax5; pax5 etv6; p13; fusion ... See more keywords
Unbiased compound screening with a reporter gene assay highlights the role of p13 in the cardiac cellular stress response.
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2017.11.116
Abstract: We recently showed that a 13-kDa protein (p13), the homolog protein of formation of mitochondrial complex V assembly factor 1 in yeast, acts as a potential protective factor in pancreatic islets under diabetes. Here, we… read more here.
Keywords: cellular stress; expression; p13; stress response ... See more keywords
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2018.1464203
Abstract: Abstract Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim to assess the efficacy and safety of switching from originator infliximab… read more here.
Keywords: response; originator; efficacy; infliximab originator ... See more keywords
Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izx092
Abstract: The introduction of biosimilars with similar efficacy and safety to the reference drug allows for more cost-effective treatment options for patients with inflammatory bowel disease (IBD).1 Infliximab (originator), marketed under the name of Remicade (RMC),… read more here.
Keywords: inflammatory bowel; rmc p13; gastroenterology; p13 ... See more keywords
Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19013
Abstract: CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical… read more here.
Keywords: infliximab; chronic plaque; p13; sb2 ... See more keywords
FRI0377 IDENTICAL TWO-YEAR TREATMENT RETENTION OF ORIGINATOR AND BIOSIMILAR INFLIXIMAB. RESULTS OF A NORDIC COLLABORATION INCLUDING 1319 PATIENTS WITH SPONDYLOARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.994
Abstract: Background The first infliximab biosimilar (CT-P13) was introduced in Europe in 2014, followed by a rapid, but differential, uptake across the Nordic countries [1]. Pre and post-marketing randomized controlled trials have shown similar efficacy and… read more here.
Keywords: p13; treatment; originator; inf ... See more keywords
Functional properties and sequence variation of HTLV-1 p13
Sign Up to like & getrecommendations! Published in 2020 at "Retrovirology"
DOI: 10.1186/s12977-020-00517-1
Abstract: Human T cell leukemia virus type-1 (HTLV-1) was the first retrovirus found to cause cancer in humans, but the mechanisms that drive the development of leukemia and other diseases associated with HTLV-1 infection remain to… read more here.
Keywords: functional properties; htlv; p13; properties sequence ... See more keywords
Knockdown of the mitochondria‐localized protein p13 protects against experimental parkinsonism
Sign Up to like & getrecommendations! Published in 2018 at "EMBO reports"
DOI: 10.15252/embr.201744860
Abstract: Mitochondrial dysfunction in the nigrostriatal dopaminergic system is a critical hallmark of Parkinson's disease (PD). Mitochondrial toxins produce cellular and behavioural dysfunctions resembling those in patients with PD. Causative gene products for familial PD play… read more here.
Keywords: mitochondria localized; protein p13; knockdown mitochondria; toxin induced ... See more keywords
CT-P13: design, development, and place in therapy
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s109852
Abstract: The introduction of biological agents has revolutionized the management of many life-threatening and debilitating immune-mediated diseases. Because of the high cost of biological drugs and their patent expiration, the market has opened to biosimilar agents,… read more here.
Keywords: therapy p13; p13; design development;